Contender to the crown
More impressive revenue growth, a strong move into Japan, and a predicted takeover of the No. 1 spot in worldwide sales among prescription drugs earned Abbott’s Humira the Med Ad News Medicine of the Year honor for a second consecutive year.
By Joshua Slatko
To the point
Troubled waters
By Christiane Truelove
20th annual report • Top 200: World’s best selling medicines
Lipitor claimed the top spot for the ninth consecutive year despite declining U.S. sales; Plavix and Advair remained at No. 2 and No. 3 for 2009; Remicade overtook Enbrel for fourth place; Seroquel and Humira make their debut in the top 10.
By Andrew Humphreys
Layers of security
By combining multiple security measures, both on drug packaging and on dose, pharmaceutical marketers are protecting the supply chain and making life difficult for the bad guys.
By Steven Niles
Prevention attention
Functional tools and cause-marketing tactics provide helpful reminders to patients and increase awareness of the dangers of disease and infection.
By Gina-Louise Monari
Sales & marketing
Pharmaceutical executives doubt that big pharma will be able to innovate sufficiently from within to replace lost revenue from patent expiration.
By Joshua Slatko
Business
Abbott's planned acquisition of Piramal Healthcare Ltd.'s Healthcare Solutions business is expected to give Abbott the No. 1 position in the Indian pharmaceutical market with a share of about 7%.
By Steven Niles
People on the Move
A new appointment at AstraZeneca aims to provide a single point of senior accountability as the company continues to improve R&D productivity and efficiency.
By Gina-Louise Monari
Ad Agency Update
A new medical education company called Group 31 Communications Inc. has risen from the ashes of the now defunct S+R Medical Communications.
By Gina-Louise Monari
Interactive & digital marketing
Two of the world's biggest pharmaceutical companies are offering physicians greater access to medical information through their mobile devices.
By Joshua Slatko
FDA Focus
If approved for opioid dependence, Alkermes Inc.'s Vivitrol would be the first and only non-narcotic, non-addictive medication for the treatment of opioid dependence available in a once-monthly formulation.
By Steven Niles
Drug approvals
FDA's approval for Genzyme Corp.'s Lumizyme marks an important milestone for patients living with late-onset Pompe disease in the United States.
By Gina-Louise Monari
Promotional analysis of the top 20 products for 2009
The competitive intelligence research company PharmaVoxx has analyzed the promotional activity of the top 20 pharmaceutical brands by revenue as ranked by Med Ad News.
By Steven Niles
Transparency 21
FDA's Transparency Task Force has released 21 draft proposals for public comment on public disclosure policies aimed at helping consumers, stakeholders, and others understand how the agency operates.
By Steven Niles
Top 100 Device Companies and New Medical Device – Review & Outlook 2010
Get qualitative analysis of newly approved medical devices and their expected market impact as well as insight into the medical device companies that are thriving in today’s fast-paced, technology-driven healthcare market. Identify industry growth drivers and opportunities. Develop strong business strategies with an understanding of key trends shaping the medical device market. PURCHASE NOW – SAVE $150!